fluoxetine has been researched along with Body Weight in 207 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study." | 9.09 | Fluoxetine-maintained obese humans: effect on food intake and body weight. ( Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS, 1999) |
| "The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit." | 9.08 | Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998) |
| "The effect of fluoxetine on body weight and spontaneous food choice was studied in twenty-three healthy, non-depressed, obese females on an outpatient basis." | 9.07 | Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. ( Koppeschaar, HP; Meinders, AE; Op de Kamp, I; Pijl, H; Veldhuis, HD; Willekens, FL, 1991) |
| "At the time of follow-up (11 +/- 6 months on fluoxetine), 29 of the 31 patients had maintained their weight at or above 85% average body weight (97% +/- 13% average body weight for the group)." | 9.07 | An open trial of fluoxetine in patients with anorexia nervosa. ( Bulik, CM; Hsu, LK; Kaye, WH; Weltzin, TE, 1991) |
| "Six patients with chronic, refractory anorexia nervosa were treated with fluoxetine." | 9.06 | Fluoxetine treatment of anorexia nervosa: an open clinical trial. ( Gainsley, B; Guze, BH; Gwirtsman, HE; Yager, J, 1990) |
| "Eleven healthy male subjects of normal body weight received either 60 mg of the 5-HT re-uptake inhibitor fluoxetine (FXT) or matching placebo daily for two weeks, with a minimum one month wash-out period between treatments." | 9.06 | The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. ( McGuirk, J; Silverstone, T, 1990) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 9.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "To examine the evidence for the use of fluoxetine in treatment of underweight and weight-restored patients with anorexia nervosa (AN) and provide recommendations for the clinical usefulness of fluoxetine in AN." | 8.89 | Use of fluoxetine in anorexia nervosa before and after weight restoration. ( Cox, S; Garris, SS; Hughes, CM; Kennedy, ML; Sebaaly, JC, 2013) |
| " The present study evaluated the effectiveness of rosmarinic acid (RA) against myocardial infarction (MI) in comorbid depression induced by maternal separation in rats." | 8.12 | Evaluation of rosmarinic acid against myocardial infarction in maternally separated rats. ( Bhattacharjee, A; Nayak, PK; Shivavedi, N; Verma, H, 2022) |
| " Here we investigated the effect of PS on ischemia-induced neovascularization, and the potential therapeutic effect of fluoxetine in this condition." | 7.81 | Psychological stress impairs ischemia-induced neovascularization: Protective effect of fluoxetine. ( Desjarlais, M; Dhahri, W; Dussault, S; Groleau, J; Haddad, P; Maingrette, F; Mathieu, R; Perez, G; Rivard, A; Turgeon, J, 2015) |
| "This study evaluated the reproductive effects of fluoxetine exposure in utero and during lactation on pregnancy outcomes and the sexual development of offspring." | 7.79 | In utero and lactational exposure to fluoxetine in Wistar rats: pregnancy outcomes and sexual development. ( Boareto, AC; Dalsenter, PR; Kienast, MF; Lourenço, EL; Martino-Andrade, AJ; Morais, RN; Müller, JC; Spercoski, KM; Zaia, RM, 2013) |
| " The aim of this study was to investigate if malnutrition and/or fluoxetine neonatal treatment program alterations in heart morphology during the postnatal period." | 7.74 | Do malnutrition and fluoxetine neonatal treatment program alterations in heart morphology? ( Amorim, MA; Aragão, Rda S; Cabral-Filho, JE; de Carvalho Filho, EV; de Moraes, SR; Manhaes-de-Castro, R; Toscano, AE, 2008) |
| " The present study examined the impact of a tryptophan-deficient diet and fluoxetine on the serotonergic regulation of neuroendocrine function and body weight." | 7.72 | Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet. ( Battaglia, G; D'Souza, DN; Garcia, F; Van de Kar, LD; Zhang, Y, 2004) |
| "The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats." | 7.70 | Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. ( Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG, 1999) |
| "Anorexia nervosa is associated with vasopressin, oxytocin and serotonin abnormalities." | 7.68 | Fluoxetine induces vasopressin and oxytocin abnormalities in food-restricted rats given voluntary exercise: relationship to anorexia nervosa. ( Ahmed, I; Aravich, PF; Lauterio, TJ; Rieg, TS, 1993) |
| "Male F344BNF1 hybrid rats (F1 crosses between female Fischer 344 and male Brown Norway rats) aged 3 or 24 months were treated with vehicle (1 ml water/kg, IP) or fluoxetine (10 mg/kg, IP) once a day for 1 day or 27 consecutive days; body weights were recorded daily." | 7.68 | Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats. ( Alper, RH, 1992) |
| "Ten outpatients meeting DSM-III-R criteria for obsessive-compulsive disorder completed a 32-week, open-label study with fluoxetine, a selective serotonin reuptake blocker." | 7.68 | Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. ( Frenkel, A; Nezu, A; Rosenthal, J; Winston, A, 1990) |
| "Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss." | 6.67 | Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 6.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| "A total of sixty male adult Wistar rats with similar body weight and age were randomly divided into 3 groups the blank control group (CON, n=20), the saline control group (SAL, n=20), and the combined medication group (Deanxit +fluoxetine, DF, n=20), then rats in group SAL and group DF were prepared for model of anxiety disorder for 14 days." | 5.51 | Changes of brain-derived neurotrophic factors in rats with generalized anxiety disorder before and after treatment. ( Du, N; Liu, YL; Ma, YY; Wang, LX; Yang, L; Yin, XL, 2022) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 5.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "Objectives Depression is tightly associated with cardiovascular comorbidity and accounts for high financial and social burden worldwide." | 5.46 | Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. ( Amiri, S; Anoush, M; Bergen, H; Haj-Mirzaian, A; Hosseini, MJ; Jafarian, I; Rahimi-Balaei, M; Sonei, N, 2017) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 5.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "Depression is associated with hippocampus (HC) volume loss." | 5.37 | The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. ( First, M; Gil-Ad, I; Novak, N; Taler, M; Tarasenko, I; Weizman, A, 2011) |
| "Fluoxetine is an anorexic agent known to reduce food intake and weight gain." | 5.33 | Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia. ( Choi, SH; Jahng, JW; Kim, BT; Lee, SY; Myung, CS; Song, GY, 2005) |
| "Fluoxetine treatment did not affect the 5-HT effect on food intake amount but significantly reduced the 5-HT effect on feeding latency." | 5.33 | Chronic fluoxetine administration desensitizes the hyperglycemia but not the anorexia induced by serotonin in rats receiving fructose-enriched chow. ( Cheng, JT; Chung, HH; Hsiao, SH; Tong, YC, 2006) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 5.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| "Fluoxetine treatment of mice restricted to 3." | 5.28 | Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. ( Dubuc, PU; Peterson, CM, 1990) |
| " Following maprotiline treatment, the body weight and BMI were significantly increased (P=0." | 5.12 | Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. ( Chen, YC; Chou, CH; Hung, YJ; Perng, CH; Shen, YC; Yeh, CB, 2007) |
| "The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study." | 5.09 | Fluoxetine-maintained obese humans: effect on food intake and body weight. ( Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS, 1999) |
| "Fluoxetine has been associated with weight loss during acute treatment, but no controlled studies of weight change during long-term treatment with fluoxetine or other selective serotonin reuptake inhibitors have been reported." | 5.09 | Changes in weight during a 1-year trial of fluoxetine. ( Amsterdam, JD; Beasley, CM; Kim, Y; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Zajecka, J, 1999) |
| "Twenty-two female patients with anorexia nervosa, restricted type, 14-35 years old, were treated with a 4-month course of combined cognitive-behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)." | 5.08 | Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type. ( Brambilla, F; Brunetta, M; Draisci, A; Peirone, A, 1995) |
| "The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit." | 5.08 | Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998) |
| "At the time of follow-up (11 +/- 6 months on fluoxetine), 29 of the 31 patients had maintained their weight at or above 85% average body weight (97% +/- 13% average body weight for the group)." | 5.07 | An open trial of fluoxetine in patients with anorexia nervosa. ( Bulik, CM; Hsu, LK; Kaye, WH; Weltzin, TE, 1991) |
| "In a double-blind trial 40 patients with bulimia nervosa according to DSM III-R criteria were randomly assigned either to a 60 mg fluoxetine group or to a placebo control group." | 5.07 | Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. ( Brunner, E; Engel, RR; Fichter, MM; Leibl, K; Rief, W; Schmidt-Auberger, S, 1991) |
| "Six patients with chronic, refractory anorexia nervosa were treated with fluoxetine." | 5.06 | Fluoxetine treatment of anorexia nervosa: an open clinical trial. ( Gainsley, B; Guze, BH; Gwirtsman, HE; Yager, J, 1990) |
| "The effects of fluoxetine, a relatively selective long-acting serotonin uptake inhibitor, on the consumption of alcoholic and nonalcoholic drinks, cigarette smoking, and body weight were assessed in 29 men who were early stage problem drinkers." | 5.06 | Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. ( Kadlec, KE; Naranjo, CA; Sanhueza, P; Sellers, EM; Woodley-Remus, D, 1990) |
| "Eleven healthy male subjects of normal body weight received either 60 mg of the 5-HT re-uptake inhibitor fluoxetine (FXT) or matching placebo daily for two weeks, with a minimum one month wash-out period between treatments." | 5.06 | The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. ( McGuirk, J; Silverstone, T, 1990) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 5.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "To examine the evidence for the use of fluoxetine in treatment of underweight and weight-restored patients with anorexia nervosa (AN) and provide recommendations for the clinical usefulness of fluoxetine in AN." | 4.89 | Use of fluoxetine in anorexia nervosa before and after weight restoration. ( Cox, S; Garris, SS; Hughes, CM; Kennedy, ML; Sebaaly, JC, 2013) |
| "The widely prescribed appetite suppressants D-fenfluramine and fluoxetine not only decrease feeding and body weight but also increase extracellular brain 5-HT." | 4.79 | Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. ( Curzon, G; Gibson, EL; Oluyomi, AO, 1997) |
| "This study investigated whether therapeutically relevant concentrations of fluoxetine, which have been shown to reduce plasma glucose and glycated haemoglobin independent of changes in food intake and body weight, regulate beta-cell function and improve glucose homeostasis." | 4.12 | The selective serotonin reuptake inhibitor fluoxetine has direct effects on beta cells, promoting insulin secretion and increasing beta-cell mass. ( Hopkins, D; Liu, B; Olaniru, OE; Persaud, SJ; Ruz-Maldonado, I; Toczyska, K; Zariwala, MG; Zhao, M, 2022) |
| " The present study evaluated the effectiveness of rosmarinic acid (RA) against myocardial infarction (MI) in comorbid depression induced by maternal separation in rats." | 4.12 | Evaluation of rosmarinic acid against myocardial infarction in maternally separated rats. ( Bhattacharjee, A; Nayak, PK; Shivavedi, N; Verma, H, 2022) |
| "In this retrospective cohort study from participants in the Mayo Clinic RIGHT study who were prescribed citalopram, paroxetine, sertraline, or fluoxetine, our aim was to evaluate the association of metabolizer phenotype and total body weight after 6 months of SSRIs initiation." | 4.12 | Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. ( Acosta, A; Bielinski, SJ; Camilleri, M; Cifuentes, L; Decker, PA; Gonzalez-Izundegui, D; Hurtado, MD; Moyer, AM; Ricardo-Silgado, ML; Singh, S, 2022) |
| " Fluoxetine (a selective serotonin reuptake inhibitor; FLX) is an agent that has been shown to delay the onset of lactogenesis stage II when taken during pregnancy and lactation in women." | 3.88 | Short communication: Effects of fluoxetine on lactation at weaning in sheep. ( Hallford, DM; Harrelson, PL; Ross, TT, 2018) |
| "We studied the effect of chronic injections of serotonin reuptake inhibitor fluoxetine to rats during pregnancy on physiological and behavioral characteristics of female offspring during the prepubertal period." | 3.88 | Effect of Fluoxetine in Prenatal Period on Nociceptive System Reactivity and Psychoemotional Behavior in Young Female Rats. ( Butkevich, IP; Mikhailenko, VA, 2018) |
| " Here we investigated the effect of PS on ischemia-induced neovascularization, and the potential therapeutic effect of fluoxetine in this condition." | 3.81 | Psychological stress impairs ischemia-induced neovascularization: Protective effect of fluoxetine. ( Desjarlais, M; Dhahri, W; Dussault, S; Groleau, J; Haddad, P; Maingrette, F; Mathieu, R; Perez, G; Rivard, A; Turgeon, J, 2015) |
| " We aimed to investigate the relationships among body weight, body mass index (BMI=kg/m(2)), change in a depression rating scale, and change in a functional scale with fluoxetine treatment for hospitalized patients with major depressive disorder (MDD)." | 3.80 | Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. ( Chen, CC; Lin, CH; McIntyre, RS; Wong, J, 2014) |
| "EOPF, as well as fluoxetine, restored the CUMS-induced decreased sucrose preference and increased immobility time, without affecting body weight gain and locomotor activity." | 3.79 | Essential oil of Perilla frutescens-induced change in hippocampal expression of brain-derived neurotrophic factor in chronic unpredictable mild stress in mice. ( Fu, Y; Geng, D; Li, J; Liu, BB; Liu, Y; Tu, JQ; Weng, LJ; Yi, LT, 2013) |
| "This study evaluated the reproductive effects of fluoxetine exposure in utero and during lactation on pregnancy outcomes and the sexual development of offspring." | 3.79 | In utero and lactational exposure to fluoxetine in Wistar rats: pregnancy outcomes and sexual development. ( Boareto, AC; Dalsenter, PR; Kienast, MF; Lourenço, EL; Martino-Andrade, AJ; Morais, RN; Müller, JC; Spercoski, KM; Zaia, RM, 2013) |
| " Behavioral state and therapeutic efficacy of the drug treatment were assessed using sucrose preference, physical state of the coat and body weight." | 3.79 | Stress-induced anhedonia correlates with lower hippocampal serotonin transporter protein expression. ( Lei, J; Liu, G; Sun, X; Tang, M; Zhao, S, 2013) |
| " Ten days of restraint increased light compartment exploration, reduced body weight and sensitized the corticosterone response to swim stress." | 3.78 | Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice. ( Fitzgerald, PJ; Hefner, KR; Holmes, A; Ihne, JL, 2012) |
| "The selective serotonin reuptake inhibitor (SSRI) Prozac® (fluoxetine) is the only registered antidepressant to treat depression in children and adolescents." | 3.77 | Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. ( Arentsen, T; Blom, T; Homberg, JR; Korte-Bouws, G; Olivier, JD; Reneman, L; Schipper, P; van Brunschot, C; van Luijtelaar, G, 2011) |
| "To investigate the effects of mirtazapine and fluoxetine, representatives of the noradrenergic and specific serotonergic antidepressant (NaSSA) and selective serotonin reuptake inhibitor (SSRI) antidepressant respectively, on body weight, ingestive behavior, locomotor activity and tumor growth of human pancreatic carcinoma xenografts in nude mice." | 3.74 | Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. ( Jia, L; Li, YY; Shang, YY, 2008) |
| " The behavioral and neuroendocrinological effects of icariin, a major constituent of flavonoids isolated from Epimedium brevicornum, were investigated in the CMS model of depression in male Wistar rats." | 3.74 | Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats. ( Jiang, FX; Kong, LD; Kung, HF; Li, YC; Pan, Y; Xia, X, 2007) |
| " The aim of this study was to investigate if malnutrition and/or fluoxetine neonatal treatment program alterations in heart morphology during the postnatal period." | 3.74 | Do malnutrition and fluoxetine neonatal treatment program alterations in heart morphology? ( Amorim, MA; Aragão, Rda S; Cabral-Filho, JE; de Carvalho Filho, EV; de Moraes, SR; Manhaes-de-Castro, R; Toscano, AE, 2008) |
| " Fluoxetine (FLX), a selective serotonin reuptake inhibitor (SSRI) antidepressant, has been widely prescribed for depression during pregnancy and/or lactation." | 3.74 | Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice. ( de Faria, MJ; Gerardin, DC; Gouvêa, TS; Moreira, EG; Morimoto, HK, 2008) |
| " We have therefore examined the effects of fluoxetine, a selective 5-HT reuptake inhibitor, and gepirone, a 5-HT1A agonist, on body weight in isolated and in group-housed rats during 3 weeks of daily treatment." | 3.72 | Influence of housing conditions on the effects of serotonergic drugs on feeding behavior in non-deprived rats. ( Brandão, ML; Santos, NR; Silva, RC, 2003) |
| " twice daily for 9 days) suppressed the development of morphine dependence as assessed by naloxone (2 mg/kg i." | 3.72 | Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways. ( Jain, NK; Kulkarni, SK; Singh, VP, 2003) |
| " The present study examined the impact of a tryptophan-deficient diet and fluoxetine on the serotonergic regulation of neuroendocrine function and body weight." | 3.72 | Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet. ( Battaglia, G; D'Souza, DN; Garcia, F; Van de Kar, LD; Zhang, Y, 2004) |
| "Injections of 10 mg/kg fluoxetine produced a significant decrease in body weight gain." | 3.71 | Destruction of serotonergic nerve terminals prevents fluoxetine-induced desensitization of hypothalamic 5-HT(1A) receptors. ( Battaglia, G; D'Souza, DN; Garcia, F; Van De Kar, LD; Zhang, Y, 2002) |
| "5, 1 and 2 g/kg, twice daily, po) of a polyherbal preparation, OB-200G and fluoxetine (10 mg/kg, ip) for 21 days was studied on food intake and body weight in male and female Laka mice." | 3.71 | Differential effect of polyherbal, antiobesity preparation, OB-200G in male and female mice and monosodium glutamate-treated rats. ( Kaur, G; Kulkarni, SK, 2001) |
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| " They also had mature onset obesity characterized by a dramatic 80-150% increase in body weight, increased linear growth, and elevated serum levels of leptin, insulin, glucose, and cholesterol." | 3.71 | Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. ( Bates, B; Fan, G; Fekete, C; Jaenisch, R; Kelly, J; Kuehn, R; Lechan, RM; Rios, M, 2001) |
| " Then, the authors also examined the effect of subchronic treatment for 21 days with fluoxetine on clozapine-induced hyperphagia and modulation of body weight and fat pad weights." | 3.71 | Studies on modulation of feeding behavior by atypical antipsychotics in female mice. ( Kaur, G; Kulkarni, SK, 2002) |
| "Chronic fluoxetine administration in obese Zucker rats generated a reduction in body weight gain, food intake, adipocyte size, fat mass, and body protein." | 3.71 | Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus. ( Abecia, LC; Casis, L; Echevarría, E; Gutiérrez, A; Macarulla, MT; Portillo, MP; Rodríguez, VM; Saracíbar, G, 2002) |
| "The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats." | 3.70 | Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. ( Altenburg, SP; da-Silva, VA; Lindsey, CJ; Malheiros, LR; Thomaz, TG, 1999) |
| "Fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, leads to reductions in food intake and body weight and is under investigation as a possible treatment for obesity." | 3.70 | Reduction of fat and protein intakes but not carbohydrate intake following acute and chronic fluoxetine in female rats. ( Heisler, LK; Homoleski, B; Kanarek, RB, 1999) |
| " To investigate this phenomenon as a possible animal model of obsessive-compulsive disorder (OCD), rats were treated for 5 weeks with fluoxetine, an antidepressant that relieves OCD symptoms in humans (5 mg/kg, 2." | 3.69 | Effects of serotonergic agents on food-restriction-induced hyperactivity. ( Altemus, M; Galliven, E; Glowa, JR; Leong, YM; Murphy, DL, 1996) |
| "Administration of fluoxetine, a selective serotonin reuptake inhibitor, results in decreases in food intake and body weight." | 3.69 | Fluoxetine decreases fat and protein intakes but not carbohydrate intake in male rats. ( Gerstein, A; Heisler, LK; Kanarek, RB, 1997) |
| "Anorexia nervosa is associated with vasopressin, oxytocin and serotonin abnormalities." | 3.68 | Fluoxetine induces vasopressin and oxytocin abnormalities in food-restricted rats given voluntary exercise: relationship to anorexia nervosa. ( Ahmed, I; Aravich, PF; Lauterio, TJ; Rieg, TS, 1993) |
| "Male F344BNF1 hybrid rats (F1 crosses between female Fischer 344 and male Brown Norway rats) aged 3 or 24 months were treated with vehicle (1 ml water/kg, IP) or fluoxetine (10 mg/kg, IP) once a day for 1 day or 27 consecutive days; body weights were recorded daily." | 3.68 | Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats. ( Alper, RH, 1992) |
| "Food intake, diet selection and body weight gain were examined in three separate experiments in which rats received saline or one of three serotonergic agonists, dexfenfluramine, RU 24969 and fluoxetine." | 3.68 | Effects of repeated administration of serotonergic agonists on diet selection and body weight in rats. ( Li, ET; Luo, SQ, 1991) |
| "Ten outpatients meeting DSM-III-R criteria for obsessive-compulsive disorder completed a 32-week, open-label study with fluoxetine, a selective serotonin reuptake blocker." | 3.68 | Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. ( Frenkel, A; Nezu, A; Rosenthal, J; Winston, A, 1990) |
| "The distribution of eating, drinking and body weight changes during the 24 hr day were examined following brain 5-HT depletion with p-chloroamphetamine (PCA)." | 3.66 | Synergistic action of p-chloroamphetamine and fluoxetine on food and water consumption patterns in the rat. ( Adler-Stein, RL; Kantak, KM; Stein, JM; Wayner, MJ, 1978) |
| "Fluoxetine treatment produced a significant weight loss of 1." | 2.68 | Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. ( Blundell, JE; Hill, AJ; Lawton, CL; Wales, JK, 1995) |
| "Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss." | 2.67 | Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993) |
| "Body weight was kept constant." | 2.67 | Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992) |
| "Fluoxetine is an inhibitor of serotonin re-uptake which has been found to produce weight loss in humans and animals." | 2.67 | A randomized double-blind clinical trial of fluoxetine in obese diabetics. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 2.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| "The body weight was determined, and behavior tests, including sucrose preference test, forced swimming test and open field test were performed." | 1.56 | Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model. ( Wang, G; Wang, H; Xiao, L, 2020) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 1.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "Melatonin has been shown to palliate different lesions by scavenging free radicals, but its role in the reduction of the fluoxetine-induced injuries has been little known." | 1.46 | Protective effects of melatonin on long-term administration of fluoxetine in rats. ( Khaksar, M; Oryan, A; Rahbarghazi, R; Rezabakhsh, A; Sayyari, M, 2017) |
| "Objectives Depression is tightly associated with cardiovascular comorbidity and accounts for high financial and social burden worldwide." | 1.46 | Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. ( Amiri, S; Anoush, M; Bergen, H; Haj-Mirzaian, A; Hosseini, MJ; Jafarian, I; Rahimi-Balaei, M; Sonei, N, 2017) |
| "Stress during pregnancy is associated with lifetime negative consequences for the offspring." | 1.46 | Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? ( Avitsur, R, 2017) |
| "Treatment of Alzheimer's disease (AD) patients with the antidepressant fluoxetine is known to improve memory and cognitive function." | 1.43 | Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice. ( de Nijs, L; Hoogland, G; Prickaerts, J; Rutten, BP; Sierksma, AS; Steinbusch, HW; van den Hove, DL; van Leeuwen, FW; Vanmierlo, T, 2016) |
| "Fluoxetine treatment was shown to cause a locomotor sensitized response to a challenge dose of amphetamine (0." | 1.39 | Increased alcohol consumption in rats after subchronic antidepressant treatment. ( Alén, F; de Fonseca, FR; de Heras, RG; Gorriti, MÁ; Orio, L; Pozo, MÁ; Ramírez-López, MT, 2013) |
| "Treatment with fluoxetine for 3 weeks abolished the neurobehavioral effects of LPS." | 1.39 | A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. ( Basta-Kaim, A; Budziszewska, B; Curzytek, K; Duda, W; Holan, V; Kubera, M; Lason, W; Leskiewicz, M; Maes, M; Roman, A; Szczesny, E; Zajicova, A, 2013) |
| " Chronic administration of an antagonist of NMDA receptors, MK-801, induced antidepressant-like effects in the TST for stressed BALB/c, but was ineffective for the hyperactivity and anhedonia-like behavior, in contrast to fluoxetine." | 1.38 | Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. ( Dumas, S; El Mestikawy, S; Farley, S; Giros, B, 2012) |
| "5-Fluorouracil (5-FU) is a cytostatic drug associated with chemotherapy-induced cognitive impairments that many cancer patients experience after treatment." | 1.38 | Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. ( Bennett, G; ElBeltagy, M; Lyons, L; Wigmore, P, 2012) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 1.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "Depression is recognized as a predictor of increased cardiac morbidity and mortality." | 1.37 | Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. ( Belzung, C; Camus, V; d'Audiffret, A; Isingrini, E, 2011) |
| "Depression is associated with hippocampus (HC) volume loss." | 1.37 | The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. ( First, M; Gil-Ad, I; Novak, N; Taler, M; Tarasenko, I; Weizman, A, 2011) |
| "Fluoxetine treatment for 21 days reduced both the pressor and tachycardiac responses evoked by acute restraint stress." | 1.37 | Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats. ( Correa, FM; Crestani, CC; Guimarães, FS; Joca, SR; Resstel, LB; Tavares, RF, 2011) |
| "Fluoxetine treatment during adolescence also impaired sexual copulatory behaviors in adulthood." | 1.36 | Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats. ( Bolaños-Guzmán, CA; Iñiguez, SD; Warren, BL, 2010) |
| "Treatment with fluoxetine between postnatal days P4 and P21 resulted in a significant loss of body weight and long-lasting behavioural inhibition in adult mice in response to stressful events such as the light-dark or open field tests." | 1.35 | Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. ( Castrén, E; Karpova, NN; Lindholm, J; Pruunsild, P; Timmusk, T, 2009) |
| "Body weight was evaluated before and after fluoxetine treatment." | 1.35 | Fluoxetine alters feeding behavior and leptin levels in chronically-stressed rats. ( Bassani, MG; Dalmaz, C; Gamaro, GD; Lopes, J; Prediger, ME, 2008) |
| "Because obesity can affect catecholaminergic signaling, we determined the effects of i." | 1.34 | Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007) |
| "Fluoxetine treatment counteracted the inhibitory effect of stress." | 1.34 | Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. ( Abumaria, N; Czéh, B; Domenici, E; Fuchs, E; Hiemke, C; Müller-Keuker, JI; Rygula, R, 2007) |
| "Fluoxetine and buspirone were significantly effective in reducing rates of self-biting during treatment weeks 1 to 8 and self-directed stereotypic behavior during weeks 5 to 12 and post-treatment." | 1.33 | The effects of fluoxetine and buspirone on self-injurious and stereotypic behavior in adult male rhesus macaques. ( De Petrillo, PB; Dupuy, AM; Fontenot, MB; Higley, JD; Lynch, CR; Padgett, EE, 2005) |
| "Fluoxetine is an anorexic agent known to reduce food intake and weight gain." | 1.33 | Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia. ( Choi, SH; Jahng, JW; Kim, BT; Lee, SY; Myung, CS; Song, GY, 2005) |
| "Fluoxetine treatment reduced body weight within the first 24 h of treatment." | 1.33 | Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats. ( Grossie, B; Hensler, JG; Sarkar, J; Uphouse, L, 2006) |
| "Fluoxetine treatment did not affect the 5-HT effect on food intake amount but significantly reduced the 5-HT effect on feeding latency." | 1.33 | Chronic fluoxetine administration desensitizes the hyperglycemia but not the anorexia induced by serotonin in rats receiving fructose-enriched chow. ( Cheng, JT; Chung, HH; Hsiao, SH; Tong, YC, 2006) |
| "Treatment with fluoxetine for 21 or 42 days produced diminished adrenocorticotropic hormone (ACTH) and oxytocin (but not corticosterone) responses to DOI injections (2." | 1.32 | Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus. ( Battaglia, G; D'Souza, DN; Damjanoska, KJ; Garcia, F; Kindel, GH; Muma, NA; Van de Kar, LD; Zhang, Y, 2003) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 1.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| "Fluoxetine treatment completely blocked the oxytocin, ACTH and corticosterone responses to 8-OH-DPAT, but did not inhibit the effect of DOI on any hormone, thus confirming that fluoxetine treatment did not produce a deficit in the functioning of corticotropin releasing hormone or oxytocin containing neurons." | 1.31 | Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors. ( Battaglia, G; DonCarlos, LL; Garcia, F; Muma, NA; Raap, DK; Van de Kar, LD, 2002) |
| "Treating leptin-deficient ob/ob and leptin receptor-deficient db/db mice with fluoxetine did not normalize body weight or rescue fertility, perhaps due to altered serotonergic tone in these animals." | 1.31 | Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction? ( Clayton, AH; Howard, LC; Moenter, SM; Sullivan, SD, 2002) |
| " At 1 and 2 weeks after the 4 d dosing regimen, acute FEN (1." | 1.30 | Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats. ( Ayestas, MA; Baumann, MH; Rothman, RB, 1998) |
| "The present studies examined the dose-response relationship of fluoxetine-induced desensitization of hypothalamic postsynaptic 5-HT1A receptors, as measured from the reduced neuroendocrine responses to a 5-HT1A agonist." | 1.30 | Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. ( Battaglia, G; Evans, S; Garcia, F; Li, Q; Muma, NA; Raap, DK; Van De Kar, LD; Wolf, WA, 1999) |
| "Low body weight was a particular risk factor." | 1.30 | Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. ( Begg, EJ; Sainsbury, R; Wilkinson, TJ; Winter, AC, 1999) |
| "Fluoxetine is a widely used serotonin reuptake inhibitor effective in the treatment of depression." | 1.29 | A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. ( Acuff-Smith, KD; Buelke-Sam, J; Fisher, JE; Moran, MS; Schilling, MA; Vorhees, CV, 1994) |
| " There was a significant shift to the right in the dose-response curve for RU24969 in the SCN in fluoxetine treated animals but a shift to the left for the dose-response curve for 8-OH-DPAT in the DRN." | 1.29 | Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro. ( Kruk, ZL; O'Connor, JJ, 1994) |
| "Fluoxetine was discontinued in 6 (15%) cases because of adverse side effects." | 1.29 | Fluoxetine in family practice patients. ( Pritchard, DC; Taylor, AT; Tollison, JW; Wagner, PJ, 1994) |
| "Body weight was decreased by 12." | 1.28 | Tianeptine, a specific serotonin uptake enhancer, decreases ethanol intake in rats. ( Compagnon, P; Daoust, M; Legrand, E; Mocaër, E, 1992) |
| "Fluoxetine treatment of mice restricted to 3." | 1.28 | Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. ( Dubuc, PU; Peterson, CM, 1990) |
| "This study compared the effects of chronic administration of anorexigenic drugs on weight loss in mice." | 1.27 | An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. ( Flood, JF; Morley, JE, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (6.76) | 18.7374 |
| 1990's | 59 (28.50) | 18.2507 |
| 2000's | 55 (26.57) | 29.6817 |
| 2010's | 64 (30.92) | 24.3611 |
| 2020's | 15 (7.25) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, XL | 1 |
| Ma, YY | 1 |
| Liu, YL | 1 |
| Wang, LX | 1 |
| Du, N | 1 |
| Yang, L | 1 |
| Zhang, Z | 1 |
| Du, Y | 1 |
| Chen, L | 1 |
| Liu, Y | 4 |
| Du, B | 1 |
| Liu, B | 1 |
| Ruz-Maldonado, I | 1 |
| Toczyska, K | 1 |
| Olaniru, OE | 1 |
| Zariwala, MG | 1 |
| Hopkins, D | 1 |
| Zhao, M | 1 |
| Persaud, SJ | 1 |
| Verma, H | 1 |
| Bhattacharjee, A | 1 |
| Shivavedi, N | 1 |
| Nayak, PK | 1 |
| Ricardo-Silgado, ML | 1 |
| Singh, S | 1 |
| Cifuentes, L | 1 |
| Decker, PA | 1 |
| Gonzalez-Izundegui, D | 1 |
| Moyer, AM | 1 |
| Hurtado, MD | 1 |
| Camilleri, M | 1 |
| Bielinski, SJ | 1 |
| Acosta, A | 1 |
| Ascencio Gutierrez, V | 1 |
| Carrillo, AA | 1 |
| Boersma, GJ | 1 |
| Tamashiro, KLK | 1 |
| Moran, TH | 4 |
| Iñiguez, SD | 5 |
| Treesukosol, Y | 4 |
| Castro, AL | 3 |
| Frankot, M | 3 |
| Chirokikh, AA | 3 |
| Uddin, SMZ | 3 |
| Areikat, N | 3 |
| Jones, R | 3 |
| Duque, E | 3 |
| Connor, C | 3 |
| Hadjiargyrou, M | 3 |
| Thanos, PK | 3 |
| Komatsu, DE | 3 |
| Cole Varela, AC | 1 |
| Soares, SM | 1 |
| Fortuna, M | 1 |
| Costa, VC | 1 |
| Piasson Barletto, Í | 1 |
| Timbola Mozatto, M | 1 |
| Siqueira, L | 1 |
| de Alcantara Barcellos, HH | 1 |
| Egydio Barreto, R | 1 |
| Gil Barcellos, LJ | 1 |
| Dorelle, LS | 1 |
| Da Cuña, RH | 1 |
| Sganga, DE | 1 |
| Rey Vázquez, G | 1 |
| López Greco, L | 1 |
| Lo Nostro, FL | 1 |
| Wang, H | 2 |
| Xiao, L | 1 |
| Wang, G | 1 |
| Braz, GRF | 3 |
| da Silva, AI | 5 |
| Silva, SCA | 2 |
| Pedroza, AAS | 1 |
| de Lemos, MDTB | 1 |
| de Lima, FAS | 1 |
| Silva, TLA | 2 |
| Lagranha, CJ | 4 |
| Peng, Y | 1 |
| Su, Y | 1 |
| Jiang, Y | 1 |
| Visco, DB | 1 |
| Manhães-de-Castro, R | 8 |
| da Silva, MM | 1 |
| Dantas-Alves, JS | 1 |
| Costa-de-Santana, BJR | 1 |
| Toscano, AE | 4 |
| Campos, RMM | 1 |
| Gouveia, HJCB | 1 |
| Lacerda, DC | 1 |
| Pereira, SDC | 1 |
| Paz, IAASG | 1 |
| Dantas Alves, JS | 1 |
| Zhu, X | 1 |
| Sun, Y | 1 |
| Zhang, C | 1 |
| Liu, H | 1 |
| Khaksar, M | 1 |
| Oryan, A | 1 |
| Sayyari, M | 1 |
| Rezabakhsh, A | 1 |
| Rahbarghazi, R | 1 |
| Pinheiro, IL | 2 |
| Reginato, A | 1 |
| da Silva Filho, RC | 1 |
| Galindo, LCM | 1 |
| Matos, RJB | 1 |
| de Souza Ferraz, JC | 1 |
| Toscano Meneses da Silva Castro, AE | 1 |
| Milanski Ferreira, M | 1 |
| Manhães de Castro, R | 1 |
| de Souza, SL | 3 |
| Harrelson, PL | 1 |
| Hallford, DM | 1 |
| Ross, TT | 1 |
| Scabia, G | 1 |
| Barone, I | 1 |
| Mainardi, M | 1 |
| Ceccarini, G | 1 |
| Scali, M | 1 |
| Buzzigoli, E | 1 |
| Dattilo, A | 1 |
| Vitti, P | 1 |
| Gastaldelli, A | 1 |
| Santini, F | 1 |
| Pizzorusso, T | 1 |
| Maffei, L | 1 |
| Maffei, M | 1 |
| Chang, HH | 1 |
| Chen, PS | 1 |
| Cheng, YW | 1 |
| Wang, TY | 1 |
| Yang, YK | 1 |
| Lu, RB | 1 |
| da L D Barros, M | 1 |
| Alves, DT | 1 |
| Quevedo, OG | 1 |
| Bonnin, A | 1 |
| Galindo, L | 1 |
| Butkevich, IP | 1 |
| Mikhailenko, VA | 1 |
| Pedroza, AADS | 1 |
| de Lima-Júnior, NC | 1 |
| Tatar, O | 1 |
| Ilhan, N | 2 |
| Susam, S | 1 |
| Ozercan, IH | 1 |
| Yi, LT | 1 |
| Li, J | 2 |
| Geng, D | 1 |
| Liu, BB | 1 |
| Fu, Y | 1 |
| Tu, JQ | 1 |
| Weng, LJ | 1 |
| Müller, JC | 1 |
| Boareto, AC | 1 |
| Lourenço, EL | 1 |
| Zaia, RM | 1 |
| Kienast, MF | 1 |
| Spercoski, KM | 1 |
| Morais, RN | 1 |
| Martino-Andrade, AJ | 1 |
| Dalsenter, PR | 1 |
| Alén, F | 1 |
| Orio, L | 1 |
| Gorriti, MÁ | 1 |
| de Heras, RG | 1 |
| Ramírez-López, MT | 1 |
| Pozo, MÁ | 1 |
| de Fonseca, FR | 1 |
| Tang, M | 1 |
| Lei, J | 1 |
| Sun, X | 1 |
| Liu, G | 1 |
| Zhao, S | 1 |
| de Oliveira, WM | 1 |
| de Sá, IR | 1 |
| de Torres, SM | 1 |
| de Morais, RN | 1 |
| Andrade, AM | 1 |
| Maia, FC | 1 |
| Tenorio, BM | 1 |
| da Silva Junior, VA | 1 |
| Yang, CR | 1 |
| Zhang, ZG | 1 |
| Bai, YY | 1 |
| Zhou, HF | 1 |
| Zhou, L | 1 |
| Ruan, CS | 1 |
| Li, F | 1 |
| Li, CQ | 1 |
| Zheng, HY | 1 |
| Shen, LJ | 1 |
| Zhou, XF | 1 |
| Schmelting, B | 1 |
| Corbach-Söhle, S | 1 |
| Kohlhause, S | 1 |
| Schlumbohm, C | 1 |
| Flügge, G | 1 |
| Fuchs, E | 3 |
| McNamara, RK | 3 |
| Able, JA | 3 |
| Jandacek, R | 3 |
| Rider, T | 3 |
| Tso, P | 3 |
| Lipton, JW | 1 |
| Sebaaly, JC | 1 |
| Cox, S | 1 |
| Hughes, CM | 1 |
| Kennedy, ML | 1 |
| Garris, SS | 1 |
| Bello, NT | 1 |
| Yeh, CY | 1 |
| Verpeut, JL | 1 |
| Walters, AL | 1 |
| Monteiro Galindo, LC | 1 |
| Nascimento, L | 1 |
| Moura Freitas, C | 1 |
| Lopes de Souza, S | 1 |
| Dringenberg, HC | 2 |
| Branfield Day, LR | 1 |
| Choi, DH | 1 |
| Lin, CH | 1 |
| Chen, CC | 1 |
| Wong, J | 1 |
| McIntyre, RS | 1 |
| Pawluski, JL | 2 |
| van Donkelaar, E | 1 |
| Abrams, Z | 1 |
| Houbart, V | 1 |
| Fillet, M | 1 |
| Steinbusch, HW | 3 |
| Charlier, TD | 1 |
| Wang, CH | 1 |
| Zhang, XL | 1 |
| Li, Y | 1 |
| Wang, GD | 1 |
| Wang, XK | 1 |
| Dong, J | 1 |
| Ning, QF | 1 |
| Habib, M | 1 |
| Shaker, S | 1 |
| El-Gayar, N | 1 |
| Aboul-Fotouh, S | 1 |
| Mirelle Costa Monteiro, H | 1 |
| Lima Barreto-Silva, N | 1 |
| Elizabete Dos Santos, G | 1 |
| de Santana Santos, A | 1 |
| Séfora Bezerra Sousa, M | 1 |
| Amâncio-Dos-Santos, Â | 1 |
| Avitsur, R | 2 |
| Levy, S | 1 |
| Grinshpahet, R | 1 |
| Goren, N | 1 |
| Hirsh, O | 1 |
| Zalko, A | 1 |
| Correia-Leite de Marcelos, PG | 1 |
| Regueira, LS | 1 |
| Santiago-Jaegger, IM | 1 |
| Cruz Perez, DE | 1 |
| de Moraes Ramos-Perez, FM | 1 |
| Evêncio Neto, J | 1 |
| Baratella-Evêncio, L | 1 |
| Maingrette, F | 1 |
| Dussault, S | 1 |
| Dhahri, W | 1 |
| Desjarlais, M | 1 |
| Mathieu, R | 1 |
| Turgeon, J | 1 |
| Haddad, P | 1 |
| Groleau, J | 1 |
| Perez, G | 1 |
| Rivard, A | 1 |
| Ding, L | 1 |
| Zhang, X | 1 |
| Guo, H | 1 |
| Yuan, J | 3 |
| Li, S | 1 |
| Hu, W | 1 |
| Golden, T | 1 |
| Wu, N | 1 |
| Galindo, LC | 1 |
| Barros, Mda L | 1 |
| Santana, RV | 1 |
| de Matos, RJ | 1 |
| Leandro, CG | 1 |
| de Castro, RM | 1 |
| Sakr, HF | 1 |
| Abbas, AM | 1 |
| Elsamanoudy, AZ | 1 |
| Ghoneim, FM | 1 |
| Sierksma, AS | 1 |
| de Nijs, L | 1 |
| Hoogland, G | 1 |
| Vanmierlo, T | 1 |
| van Leeuwen, FW | 1 |
| Rutten, BP | 1 |
| Prickaerts, J | 2 |
| van den Hove, DL | 2 |
| Sonei, N | 1 |
| Amiri, S | 1 |
| Jafarian, I | 1 |
| Anoush, M | 1 |
| Rahimi-Balaei, M | 1 |
| Bergen, H | 1 |
| Haj-Mirzaian, A | 1 |
| Hosseini, MJ | 1 |
| Li, YC | 3 |
| Liu, YM | 1 |
| Shen, JD | 1 |
| Chen, JJ | 1 |
| Pei, YY | 1 |
| Fang, XY | 1 |
| Tassabehji, NM | 1 |
| Corniola, RS | 1 |
| Alshingiti, A | 1 |
| Levenson, CW | 1 |
| Jia, L | 1 |
| Shang, YY | 1 |
| Li, YY | 1 |
| Kaplan, AS | 1 |
| Walsh, BT | 2 |
| Olmsted, M | 1 |
| Attia, E | 2 |
| Carter, JC | 1 |
| Devlin, MJ | 1 |
| Pike, KM | 1 |
| Woodside, B | 1 |
| Rockert, W | 1 |
| Roberto, CA | 1 |
| Parides, M | 1 |
| Karpova, NN | 1 |
| Lindholm, J | 1 |
| Pruunsild, P | 1 |
| Timmusk, T | 1 |
| Castrén, E | 2 |
| O'Leary, OF | 1 |
| Wu, X | 1 |
| Mutlu, O | 1 |
| Ulak, G | 1 |
| Laugeray, A | 1 |
| Belzung, C | 2 |
| Wang, FM | 1 |
| Pan, Y | 2 |
| Qiang, LQ | 1 |
| Cheng, G | 1 |
| Zhang, WY | 1 |
| Kong, LD | 2 |
| Ferreira-E-Silva, WT | 1 |
| Galvão, BA | 1 |
| Ferraz-Pereira, KN | 1 |
| de-Castro, CB | 1 |
| Lee, LJ | 1 |
| Bianchi, M | 1 |
| Fone, KC | 1 |
| Shah, AJ | 1 |
| Atkins, AR | 1 |
| Dawson, LA | 1 |
| Heidbreder, CA | 1 |
| Hagan, JJ | 1 |
| Marsden, CA | 1 |
| Warren, BL | 1 |
| Bolaños-Guzmán, CA | 1 |
| Czyzyk, TA | 1 |
| Sahr, AE | 1 |
| Statnick, MA | 1 |
| Silva, CM | 1 |
| Gonçalves, L | 1 |
| Nogueira, MI | 2 |
| Laino, CH | 1 |
| Fonseca, C | 1 |
| Sterin-Speziale, N | 1 |
| Slobodianik, N | 1 |
| Reinés, A | 1 |
| Homberg, JR | 1 |
| Olivier, JD | 1 |
| Blom, T | 1 |
| Arentsen, T | 1 |
| van Brunschot, C | 1 |
| Schipper, P | 1 |
| Korte-Bouws, G | 1 |
| van Luijtelaar, G | 1 |
| Reneman, L | 1 |
| Isingrini, E | 1 |
| d'Audiffret, A | 1 |
| Camus, V | 1 |
| First, M | 1 |
| Gil-Ad, I | 1 |
| Taler, M | 1 |
| Tarasenko, I | 1 |
| Novak, N | 1 |
| Weizman, A | 1 |
| Estrada-Camarena, E | 1 |
| López-Rubalcava, C | 1 |
| Hernández-Aragón, A | 1 |
| Mejía-Mauries, S | 1 |
| Picazo, O | 1 |
| Olivares, EL | 1 |
| Silva-Almeida, C | 1 |
| Pestana, FM | 1 |
| Sonoda-Côrtes, R | 1 |
| Araujo, IG | 1 |
| Rodrigues, NC | 1 |
| Mecawi, AS | 1 |
| Côrtes, WS | 1 |
| Marassi, MP | 1 |
| Reis, LC | 1 |
| Rocha, FF | 1 |
| Ihne, JL | 1 |
| Fitzgerald, PJ | 1 |
| Hefner, KR | 1 |
| Holmes, A | 1 |
| Rayen, I | 1 |
| Farley, S | 1 |
| Dumas, S | 1 |
| El Mestikawy, S | 1 |
| Giros, B | 1 |
| Crestani, CC | 1 |
| Tavares, RF | 1 |
| Guimarães, FS | 1 |
| Correa, FM | 1 |
| Joca, SR | 1 |
| Resstel, LB | 1 |
| Vorhees, CV | 2 |
| Morford, LR | 1 |
| Graham, DL | 1 |
| Skelton, MR | 1 |
| Williams, MT | 1 |
| Guirado, R | 1 |
| Sanchez-Matarredona, D | 1 |
| Varea, E | 1 |
| Crespo, C | 1 |
| Blasco-Ibáñez, JM | 1 |
| Nacher, J | 1 |
| Lyons, L | 1 |
| ElBeltagy, M | 1 |
| Bennett, G | 1 |
| Wigmore, P | 1 |
| Yu, J | 1 |
| Stewart Agras, W | 1 |
| Halmi, KA | 1 |
| Crow, S | 1 |
| Mitchell, J | 1 |
| Bryson, SW | 1 |
| Klenotich, SJ | 1 |
| Seiglie, MP | 1 |
| McMurray, MS | 1 |
| Roitman, JD | 1 |
| Le Grange, D | 1 |
| Dugad, P | 1 |
| Dulawa, SC | 1 |
| Lauzurica, N | 1 |
| García-García, L | 1 |
| Fuentes, JA | 1 |
| Delgado, M | 1 |
| Heinen, M | 1 |
| Hettich, MM | 1 |
| Ryan, DP | 1 |
| Schnell, S | 1 |
| Paesler, K | 1 |
| Ehninger, D | 1 |
| McAllister, BB | 1 |
| Kiryanova, V | 1 |
| Dyck, RH | 1 |
| Yoo, SB | 1 |
| Kim, BT | 2 |
| Kim, JY | 1 |
| Ryu, V | 1 |
| Kang, DW | 1 |
| Lee, JH | 1 |
| Jahng, JW | 2 |
| Yu, Y | 1 |
| Wang, R | 1 |
| Chen, C | 1 |
| Du, X | 1 |
| Ruan, L | 1 |
| Sun, J | 1 |
| Zhang, L | 1 |
| O'Donnell, JM | 1 |
| Pan, J | 1 |
| Xu, Y | 1 |
| Doosti, MH | 1 |
| Bakhtiari, A | 1 |
| Zare, P | 1 |
| Amani, M | 1 |
| Majidi-Zolbanin, N | 1 |
| Babri, S | 1 |
| Salari, AA | 1 |
| Kubera, M | 1 |
| Curzytek, K | 1 |
| Duda, W | 1 |
| Leskiewicz, M | 1 |
| Basta-Kaim, A | 1 |
| Budziszewska, B | 1 |
| Roman, A | 1 |
| Zajicova, A | 1 |
| Holan, V | 1 |
| Szczesny, E | 1 |
| Lason, W | 1 |
| Maes, M | 1 |
| Van de Kar, LD | 7 |
| Raap, DK | 3 |
| Battaglia, G | 7 |
| Muma, NA | 3 |
| Garcia, F | 7 |
| DonCarlos, LL | 1 |
| Arnold, LM | 1 |
| McElroy, SL | 1 |
| Hudson, JI | 2 |
| Welge, JA | 1 |
| Bennett, AJ | 1 |
| Keck, PE | 1 |
| D'Souza, DN | 3 |
| Zhang, Y | 5 |
| Kaur, G | 2 |
| Kulkarni, SK | 3 |
| Mendes-da-Silva, C | 1 |
| Barreto-Medeiros, JM | 1 |
| de Freitas-Silva, SR | 1 |
| Antunes, DE | 1 |
| Cunha, AD | 1 |
| Ribas, VR | 1 |
| de França, MF | 1 |
| Silva, RC | 1 |
| Santos, NR | 1 |
| Brandão, ML | 1 |
| Damjanoska, KJ | 1 |
| Kindel, GH | 1 |
| Wellman, PJ | 1 |
| Jones, SL | 1 |
| Miller, DK | 1 |
| Singh, VP | 1 |
| Jain, NK | 1 |
| Kamei, J | 1 |
| Miyata, S | 1 |
| Morita, K | 1 |
| Saitoh, A | 1 |
| Takeda, H | 1 |
| Horowitz, JM | 1 |
| Goyal, A | 1 |
| Ramdeen, N | 1 |
| Hallas, BH | 1 |
| Horowitz, AT | 1 |
| Torres, G | 1 |
| Thompson, MR | 1 |
| Li, KM | 1 |
| Clemens, KJ | 1 |
| Gurtman, CG | 1 |
| Hunt, GE | 1 |
| Cornish, JL | 1 |
| McGregor, IS | 1 |
| Papakostas, GI | 1 |
| Petersen, T | 1 |
| Iosifescu, DV | 1 |
| Burns, AM | 1 |
| Nierenberg, AA | 2 |
| Alpert, JE | 1 |
| Rosenbaum, JF | 3 |
| Fava, M | 2 |
| Churruca, I | 2 |
| Portillo, MP | 3 |
| Gutiérreza, A | 1 |
| Casis, L | 3 |
| Macarulla, MT | 3 |
| Zarate, J | 1 |
| Echevarría, E | 3 |
| Fontenot, MB | 1 |
| Padgett, EE | 1 |
| Dupuy, AM | 1 |
| Lynch, CR | 1 |
| De Petrillo, PB | 1 |
| Higley, JD | 1 |
| Meers, L | 1 |
| Odberg, FO | 1 |
| Myung, CS | 1 |
| Choi, SH | 1 |
| Song, GY | 1 |
| Lee, SY | 1 |
| Landry, M | 1 |
| Frasier, M | 1 |
| Chen, Z | 1 |
| Grippo, AJ | 1 |
| Beltz, TG | 1 |
| Weiss, RM | 1 |
| Johnson, AK | 1 |
| Goldstein, DJ | 2 |
| Rampey, AH | 1 |
| Dornseif, BE | 1 |
| Levine, LR | 1 |
| Potvin, JH | 1 |
| Fludzinski, LA | 1 |
| Visser, M | 1 |
| Seidell, JC | 1 |
| Koppeschaar, HP | 2 |
| Smits, P | 1 |
| Uphouse, L | 1 |
| Hensler, JG | 1 |
| Sarkar, J | 1 |
| Grossie, B | 1 |
| dos Santos, AA | 1 |
| Pinheiro, PC | 1 |
| de Lima, DS | 1 |
| Ozias, MG | 1 |
| de Oliveira, MB | 1 |
| Guimarães, NX | 1 |
| Guedes, RC | 1 |
| Hsiao, SH | 1 |
| Chung, HH | 1 |
| Tong, YC | 1 |
| Cheng, JT | 1 |
| Billes, SK | 1 |
| Cowley, MA | 1 |
| Rygula, R | 2 |
| Abumaria, N | 2 |
| Domenici, E | 2 |
| Hiemke, C | 2 |
| Czéh, B | 1 |
| Müller-Keuker, JI | 1 |
| Bhansali, P | 1 |
| Dunning, J | 1 |
| Singer, SE | 1 |
| David, L | 1 |
| Schmauss, C | 1 |
| Chen, YC | 1 |
| Shen, YC | 1 |
| Hung, YJ | 1 |
| Chou, CH | 1 |
| Yeh, CB | 1 |
| Perng, CH | 1 |
| Xia, X | 1 |
| Kung, HF | 1 |
| Jiang, FX | 1 |
| Gutiérrez, A | 2 |
| Gamaro, GD | 1 |
| Prediger, ME | 1 |
| Lopes, J | 1 |
| Bassani, MG | 1 |
| Dalmaz, C | 1 |
| Amorim, MA | 1 |
| de Carvalho Filho, EV | 1 |
| Aragão, Rda S | 1 |
| Cabral-Filho, JE | 1 |
| de Moraes, SR | 1 |
| McAdam, TD | 1 |
| Brien, JF | 1 |
| Reynolds, JN | 1 |
| Gouvêa, TS | 1 |
| Morimoto, HK | 1 |
| de Faria, MJ | 1 |
| Moreira, EG | 1 |
| Gerardin, DC | 1 |
| Verberne, AJ | 1 |
| Taylor, DA | 1 |
| Fennessy, MR | 1 |
| Bremner, JD | 1 |
| Brambilla, F | 1 |
| Draisci, A | 1 |
| Peirone, A | 1 |
| Brunetta, M | 1 |
| McCann, UD | 1 |
| Ricaurte, GA | 2 |
| Trouvin, JH | 1 |
| Gardier, AM | 1 |
| Chanut, E | 1 |
| Pages, N | 1 |
| Jacquot, C | 1 |
| Bell, RC | 1 |
| Lanou, AJ | 1 |
| Frongillo, EA | 1 |
| Levitsky, DA | 1 |
| Campbell, TC | 1 |
| Tejani-Butt, SM | 2 |
| Paré, WP | 1 |
| Yang, J | 2 |
| Acuff-Smith, KD | 1 |
| Schilling, MA | 1 |
| Fisher, JE | 1 |
| Moran, MS | 1 |
| Buelke-Sam, J | 1 |
| O'Connor, JJ | 1 |
| Kruk, ZL | 1 |
| Taylor, AT | 1 |
| Wagner, PJ | 1 |
| Pritchard, DC | 1 |
| Tollison, JW | 1 |
| Byrd, RA | 1 |
| Markham, JK | 1 |
| Aravich, PF | 1 |
| Rieg, TS | 1 |
| Ahmed, I | 1 |
| Lauterio, TJ | 1 |
| Fletcher, PJ | 1 |
| Currie, PJ | 1 |
| Chambers, JW | 1 |
| Coscina, DV | 1 |
| Szarek, BL | 1 |
| Brandt, DM | 1 |
| Lawton, CL | 1 |
| Wales, JK | 1 |
| Hill, AJ | 1 |
| Blundell, JE | 1 |
| Carter, WP | 1 |
| Pope, HG | 1 |
| Invernizzi, R | 1 |
| Bramante, M | 1 |
| Samanin, R | 1 |
| Dryden, S | 1 |
| Frankish, HM | 1 |
| Wang, Q | 1 |
| Pickavance, L | 1 |
| Williams, G | 1 |
| Jordaan, GP | 1 |
| Roberts, MC | 1 |
| Emsley, RA | 1 |
| Altemus, M | 1 |
| Glowa, JR | 1 |
| Galliven, E | 1 |
| Leong, YM | 1 |
| Murphy, DL | 1 |
| Pava, JA | 1 |
| Clancy, K | 1 |
| Curzon, G | 1 |
| Gibson, EL | 1 |
| Oluyomi, AO | 1 |
| Caccia, S | 1 |
| Confalonieri, S | 1 |
| Bergami, A | 1 |
| Fracasso, C | 1 |
| Anelli, M | 1 |
| Garattini, S | 1 |
| Heisler, LK | 2 |
| Kanarek, RB | 2 |
| Gerstein, A | 1 |
| Pellegrino, TC | 1 |
| Bayer, BM | 1 |
| Haiman, C | 1 |
| Flater, SR | 1 |
| Varner, RV | 1 |
| Ruiz, P | 1 |
| Small, DR | 1 |
| Vega Matuszcyk, J | 1 |
| Larsson, K | 1 |
| Eriksson, E | 1 |
| Ukai, M | 1 |
| Maeda, H | 1 |
| Nanya, Y | 1 |
| Kameyama, T | 1 |
| Matsuno, K | 1 |
| Baumann, MH | 1 |
| Ayestas, MA | 1 |
| Rothman, RB | 1 |
| Evans, S | 1 |
| Li, Q | 1 |
| Wolf, WA | 1 |
| Wilkinson, TJ | 1 |
| Begg, EJ | 1 |
| Winter, AC | 1 |
| Sainsbury, R | 1 |
| da-Silva, VA | 1 |
| Altenburg, SP | 1 |
| Malheiros, LR | 1 |
| Thomaz, TG | 1 |
| Lindsey, CJ | 1 |
| Ward, AS | 1 |
| Comer, SD | 1 |
| Haney, M | 1 |
| Fischman, MW | 1 |
| Foltin, RW | 1 |
| Homoleski, B | 1 |
| Cantor, JM | 1 |
| Binik, YM | 1 |
| Pfaus, JG | 1 |
| Michelson, D | 1 |
| Amsterdam, JD | 2 |
| Quitkin, FM | 1 |
| Reimherr, FW | 1 |
| Zajecka, J | 1 |
| Sundell, KL | 1 |
| Kim, Y | 1 |
| Beasley, CM | 1 |
| Shearman, LP | 1 |
| Meyer, JS | 1 |
| Serres, F | 1 |
| Ma, Q | 1 |
| Kalia, M | 1 |
| O'Callaghan, JP | 1 |
| Miller, DB | 1 |
| Kramer, M | 1 |
| Cash, TF | 1 |
| Brown, MA | 1 |
| Callahan, BT | 1 |
| Gendall, KA | 1 |
| Joyce, PR | 1 |
| Mulder, RT | 1 |
| Sullivan, PF | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
| Markou, A | 1 |
| Rios, M | 1 |
| Fan, G | 1 |
| Fekete, C | 1 |
| Kelly, J | 1 |
| Bates, B | 1 |
| Kuehn, R | 1 |
| Lechan, RM | 1 |
| Jaenisch, R | 1 |
| Mallinckrodt, C | 1 |
| Lu, Y | 1 |
| Demitrack, MA | 1 |
| Sullivan, SD | 1 |
| Howard, LC | 1 |
| Clayton, AH | 1 |
| Moenter, SM | 1 |
| Saracíbar, G | 1 |
| Rodríguez, VM | 1 |
| Abecia, LC | 1 |
| Stein, JM | 1 |
| Wayner, MJ | 1 |
| Kantak, KM | 1 |
| Adler-Stein, RL | 1 |
| Potter van Loon, BJ | 1 |
| Radder, JK | 1 |
| Frölich, M | 1 |
| Krans, HM | 1 |
| Zwinderman, AH | 1 |
| Meinders, AE | 2 |
| Gray, DS | 1 |
| Fujioka, K | 1 |
| Devine, W | 1 |
| Bray, GA | 1 |
| McGuirk, J | 2 |
| Muscat, R | 1 |
| Willner, P | 1 |
| Daoust, M | 1 |
| Compagnon, P | 1 |
| Legrand, E | 1 |
| Mocaër, E | 1 |
| Alper, RH | 1 |
| Pijl, H | 1 |
| Willekens, FL | 1 |
| Op de Kamp, I | 1 |
| Veldhuis, HD | 1 |
| Kaye, WH | 1 |
| Weltzin, TE | 1 |
| Hsu, LK | 1 |
| Bulik, CM | 1 |
| de Jonghe, F | 1 |
| Ravelli, DP | 1 |
| Tuynman-Qua, H | 1 |
| Feighner, JP | 2 |
| Gardner, EA | 1 |
| Johnston, JA | 1 |
| Batey, SR | 1 |
| Khayrallah, MA | 1 |
| Ascher, JA | 1 |
| Lineberry, CG | 1 |
| Fichter, MM | 1 |
| Leibl, K | 1 |
| Rief, W | 1 |
| Brunner, E | 1 |
| Schmidt-Auberger, S | 1 |
| Engel, RR | 1 |
| Folgelson, DL | 1 |
| Luo, SQ | 1 |
| Li, ET | 1 |
| Frenkel, A | 1 |
| Rosenthal, J | 1 |
| Nezu, A | 1 |
| Winston, A | 1 |
| Gwirtsman, HE | 1 |
| Guze, BH | 1 |
| Yager, J | 1 |
| Gainsley, B | 1 |
| Dubuc, PU | 1 |
| Peterson, CM | 1 |
| Orzack, MH | 1 |
| Friedman, LM | 1 |
| Marby, DW | 1 |
| Solyom, L | 1 |
| Solyom, C | 1 |
| Ledwidge, B | 1 |
| Naranjo, CA | 1 |
| Kadlec, KE | 1 |
| Sanhueza, P | 1 |
| Woodley-Remus, D | 1 |
| Sellers, EM | 1 |
| Silverstone, T | 1 |
| Schweizer, E | 1 |
| Rickels, K | 1 |
| Fox, I | 1 |
| Puzzuoli, G | 1 |
| Weise, C | 1 |
| Corne, SJ | 1 |
| Hall, JR | 1 |
| Altamura, AC | 1 |
| De Novellis, F | 1 |
| Guercetti, G | 1 |
| Invernizzi, G | 1 |
| Percudani, M | 1 |
| Montgomery, SA | 1 |
| Grupp, LA | 1 |
| Perlanski, E | 1 |
| Stewart, RB | 1 |
| Morley, JE | 1 |
| Flood, JF | 1 |
| Harto, NE | 1 |
| Spera, KF | 1 |
| Branconnier, RJ | 1 |
| Levine, S | 1 |
| Deo, R | 1 |
| Mahadevan, K | 1 |
| Wilcox, JA | 1 |
| Ferguson, JM | 1 |
| Cohn, JB | 2 |
| Wilcox, C | 1 |
| Chouinard, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
5 reviews available for fluoxetine and Body Weight
| Article | Year |
|---|---|
Effects of the selective serotonin reuptake inhibitor fluoxetine on glucose metabolism: A systematic review.
Topics: Antidepressive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fluoxetine; Glucose; H | 2022 |
Long term effects of neonatal exposure to fluoxetine on energy balance: A systematic review of experimental studies.
Topics: Animals; Body Weight; Energy Metabolism; Feeding Behavior; Fluoxetine; Hypothalamus; Mitochondria; M | 2018 |
Use of fluoxetine in anorexia nervosa before and after weight restoration.
Topics: Anorexia Nervosa; Antidepressive Agents, Second-Generation; Body Weight; Fluoxetine; Humans; Selecti | 2013 |
Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Body Weight; Bulimia; Clinical Trials as To | 1996 |
Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.
Topics: Appetite Depressants; Body Weight; Brain; Dopamine Agonists; Eating; Female; Fenfluramine; Fluoxetin | 1997 |
38 trials available for fluoxetine and Body Weight
| Article | Year |
|---|---|
Changes of brain-derived neurotrophic factors in rats with generalized anxiety disorder before and after treatment.
Topics: Animals; Anxiety Disorders; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Fluoxetine; Male; | 2022 |
The slippery slope: prediction of successful weight maintenance in anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Image; Body Mass Index; Body Weight; Cognitive Behavioral | 2009 |
A 1-year follow-up of a multi-center treatment trial of adults with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Weight; Cognitive Behavioral Therapy; Combined Modality Therapy; Femal | 2011 |
A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder.
Topics: Adult; Body Mass Index; Body Weight; Bulimia; Dose-Response Relationship, Drug; Double-Blind Method; | 2002 |
Obesity among outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depr | 2005 |
Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Carbohydrates; Cholesterol; Cholesterol, LDL; | 1993 |
No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity.
Topics: Abdominal Fat; Adult; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Double-Blind | 1994 |
Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Blood Glucose; Body M | 2007 |
Fluoxetine in depressed patients: a comparison with imipramine.
Topics: Adult; Aged; Ambulatory Care; Body Weight; Clinical Trials as Topic; Depressive Disorder; Double-Bli | 1984 |
Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antidepressive Agents | 1995 |
Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects.
Topics: Adult; Body Weight; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats; Double-Blind Method; Ea | 1995 |
Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Depressive Disor | 1996 |
Does fluoxetine augment the inpatient treatment of anorexia nervosa?
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Combined Modality Therapy; Depressive Disorder; Do | 1998 |
Fluoxetine-maintained obese humans: effect on food intake and body weight.
Topics: Adult; Affect; Analysis of Variance; Body Weight; Eating; Female; Fluoxetine; Humans; Male; Obesity; | 1999 |
Changes in weight during a 1-year trial of fluoxetine.
Topics: Adult; Appetite; Body Mass Index; Body Weight; Depressive Disorder; Female; Fluoxetine; Humans; Male | 1999 |
Attitudes about antidepressants: influence of information about weight-related side effects.
Topics: Adolescent; Adult; Antidepressive Agents; Attitude to Health; Body Weight; Drug Information Services | 2000 |
The effects of fluoxetine versus nortriptyline on body weight in depression.
Topics: Adrenergic Uptake Inhibitors; Body Weight; Female; Fluoxetine; Humans; Male; Mood Disorders; Nortrip | 2000 |
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Pressure; Body Weight; Depressive | 2002 |
Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose; Glu | 1992 |
A randomized double-blind clinical trial of fluoxetine in obese diabetics.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Femal | 1992 |
Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity.
Topics: Adult; Body Mass Index; Body Weight; Brain; Energy Intake; Female; Fluoxetine; Food Preferences; Hum | 1991 |
An open trial of fluoxetine in patients with anorexia nervosa.
Topics: Adolescent; Adult; Ambulatory Care; Anorexia Nervosa; Body Weight; Bulimia; Female; Fluoxetine; Foll | 1991 |
A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.
Topics: Adolescent; Adult; Aged; Body Weight; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; | 1991 |
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Body Weight; Bupropion; Depressive Disorder; Dose-Res | 1991 |
Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy.
Topics: Adult; Body Weight; Bulimia; Double-Blind Method; Female; Fluoxetine; Humans; Male; Psychiatric Stat | 1991 |
Fluoxetine treatment of anorexia nervosa: an open clinical trial.
Topics: Adult; Anorexia Nervosa; Body Weight; Contraindications; Depressive Disorder; Female; Fluoxetine; Hu | 1990 |
Weight changes on fluoxetine as a function of baseline weight in depressed outpatients.
Topics: Adult; Aged; Body Weight; Depression; Double-Blind Method; Doxepin; Female; Fluoxetine; Humans; Male | 1990 |
Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers.
Topics: Adult; Alcohol Drinking; Alcoholism; Analysis of Variance; Appetite; Body Weight; Drinking Behavior; | 1990 |
The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects.
Topics: Adolescent; Adult; Appetite; Body Weight; Double-Blind Method; Energy Intake; Fluoxetine; Humans; Ma | 1990 |
What constitutes an adequate antidepressant trial for fluoxetine?
Topics: Adult; Body Weight; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, Drug; | 1990 |
A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice.
Topics: Adolescent; Adult; Aged; Body Weight; Clinical Trials as Topic; Depression; Dibenzothiepins; Dothiep | 1989 |
Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial.
Topics: Aged; Amitriptyline; Appetite; Body Weight; Depressive Disorder; Double-Blind Method; Female; Fluoxe | 1989 |
Fluoxetine-induced reduction of body mass in patients with major depressive disorder.
Topics: Adult; Body Weight; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged | 1988 |
A comparative trial of a new antidepressant, fluoxetine.
Topics: Adult; Aged; Body Weight; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female | 1987 |
Fluoxetine-induced weight loss in overweight, nondepressed subjects.
Topics: Adolescent; Adult; Aged; Appetite; Body Weight; Clinical Trials as Topic; Double-Blind Method; Femal | 1986 |
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder.
Topics: Age Factors; Aged; Anxiety; Blood Pressure; Body Weight; Clinical Trials as Topic; Depressive Disord | 1985 |
A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.
Topics: Adult; Ambulatory Care; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Disorder; Dizzine | 1985 |
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Amitriptyline; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Di | 1985 |
164 other studies available for fluoxetine and Body Weight
| Article | Year |
|---|---|
The selective serotonin reuptake inhibitor fluoxetine has direct effects on beta cells, promoting insulin secretion and increasing beta-cell mass.
Topics: Animals; Body Weight; Fluoxetine; Glucose; Humans; Insulin; Insulin Secretion; Islets of Langerhans; | 2022 |
Evaluation of rosmarinic acid against myocardial infarction in maternally separated rats.
Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; Cinnamates; Corticosterone; Depsides; Fluox | 2022 |
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Topics: Body Weight; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; | 2022 |
Effect of early-life stress or fluoxetine exposure on later-life conditioned taste aversion learning in Sprague-Dawley rats.
Topics: Animals; Avoidance Learning; Body Weight; Female; Fluoxetine; Lithium Chloride; Male; Prenatal Expos | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Acute and long-lasting effects of adolescent fluoxetine exposure on feeding behavior in Sprague-Dawley rats.
Topics: Animals; Body Weight; Diet; Feeding Behavior; Female; Fluoxetine; Male; Rats; Rats, Sprague-Dawley | 2022 |
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development.
Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain | 2023 |
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development.
Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain | 2023 |
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development.
Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain | 2023 |
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development.
Topics: Animals; Body Weight; Fluoxetine; Male; Methylphenidate; Rats; Rats, Sprague-Dawley; Weight Gain | 2023 |
A single exposure to sub-lethal concentrations of a glyphosate-based herbicide or fluoxetine-based agent on growth performance in Nile tilapia.
Topics: Animals; Body Weight; Cichlids; Fluoxetine; Glyphosate; Herbicides | 2023 |
Fluoxetine exposure disrupts food intake and energy storage in the cichlid fish Cichlasoma dimerus (Teleostei, Cichliformes).
Topics: Animals; Body Weight; Cichlids; Eating; Energy Metabolism; Feeding Behavior; Fluoxetine; Hypothalamu | 2020 |
Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Body Weight; Depression; Fluoxetine; Food | 2020 |
Chronic serotonin reuptake inhibition uncouples brown fat mitochondria and induces beiging/browning process of white fat in overfed rats.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Body Weight; Fluoxetine; Male; Mitochondria; | 2020 |
Effect of the warming and tonifying kidney- yang recipe on monoamine neurotransmitters and pathological morphology of hippocampus tissue in depression model rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Biogenic Monoamines; Body Weight; Depression; Dis | 2020 |
Early life fluoxetine treatment causes long-term lean phenotype in skeletal muscle of rats exposed to maternal lard-based high-fat diet.
Topics: Animals; Animals, Newborn; Body Weight; Citrate (si)-Synthase; Diet, High-Fat; Dietary Fats; Eating; | 2020 |
Neonatal fluoxetine exposure delays reflex ontogeny, somatic development, and food intake similarly in male and female rats.
Topics: Animals; Body Weight; Female; Fluoxetine; Male; Pregnancy; Rats; Selective Serotonin Reuptake Inhibi | 2021 |
Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays.
Topics: Animals; Behavior, Animal; Berberine; Bifidobacterium; Body Weight; Depression; Disease Models, Anim | 2017 |
Protective effects of melatonin on long-term administration of fluoxetine in rats.
Topics: Animals; Antioxidants; Body Weight; Drug-Related Side Effects and Adverse Reactions; Erythrocyte Cou | 2017 |
Neonatal fluoxetine exposure modulates serotonergic neurotransmission and disturb inhibitory action of serotonin on food intake.
Topics: Age Factors; Animals; Animals, Newborn; Body Weight; Citalopram; Eating; Female; Fluoxetine; Food De | 2019 |
Short communication: Effects of fluoxetine on lactation at weaning in sheep.
Topics: Animals; Body Weight; Female; Fluoxetine; Lactation; Milk; Pregnancy; Selective Serotonin Reuptake I | 2018 |
The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF.
Topics: Adipose Tissue, White; Animals; Antidepressive Agents; Body Weight; Brain-Derived Neurotrophic Facto | 2018 |
FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Drug Therapy, Co | 2018 |
Effect of Fluoxetine in Prenatal Period on Nociceptive System Reactivity and Psychoemotional Behavior in Young Female Rats.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Cognition; Female; Fluoxetine; Ma | 2018 |
Body composition, biochemical, behavioral and molecular alterations in overfed rats after chronic exposure to SSRI.
Topics: Animals; Behavior, Animal; Body Composition; Body Weight; Eating; Energy Metabolism; Fluoxetine; Hyp | 2019 |
Is there any potential anticancer effect of raloxifene and fluoxetine on DMBA-induced rat breast cancer?
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Carcinogens; Enzyme-L | 2019 |
Essential oil of Perilla frutescens-induced change in hippocampal expression of brain-derived neurotrophic factor in chronic unpredictable mild stress in mice.
Topics: alpha-Linolenic Acid; Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Brain-Derived N | 2013 |
In utero and lactational exposure to fluoxetine in Wistar rats: pregnancy outcomes and sexual development.
Topics: Animals; Animals, Newborn; Body Weight; Dose-Response Relationship, Drug; Estrogens; Female; Fluoxet | 2013 |
Increased alcohol consumption in rats after subchronic antidepressant treatment.
Topics: Alcohol Drinking; Alcohols; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Addictiv | 2013 |
Stress-induced anhedonia correlates with lower hippocampal serotonin transporter protein expression.
Topics: Analysis of Variance; Anhedonia; Animals; Body Weight; Disease Models, Animal; Fluoxetine; Food Pref | 2013 |
Perinatal exposure to fluoxetine via placenta and lactation inhibits the testicular development in male rat offspring.
Topics: Animals; Body Weight; Female; Fluoxetine; Lactation; Male; Maternal Exposure; Organ Size; Pregnancy; | 2013 |
Foraging activity is reduced in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Appetitive Behavior; Body Weight; Cerebral Cortex; Chronic Disease; | 2014 |
Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status.
Topics: Acetamides; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Temperatu | 2014 |
Omega-3 fatty acid deficiency does not alter the effects of chronic fluoxetine treatment on central serotonin turnover or behavior in the forced swim test in female rats.
Topics: Animals; Base Sequence; Behavior, Animal; Body Weight; Brain Stem; Chromatography, Gas; Chromatograp | 2013 |
Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression.
Topics: alpha-Linolenic Acid; Animals; Body Weight; Brain; Diet; Fatty Acids, Omega-3; Fluoxetine; Male; Mot | 2014 |
Binge-like eating attenuates nisoxetine feeding suppression, stress activation, and brain norepinephrine activity.
Topics: Animals; Body Weight; Brain; Bulimia; Energy Intake; Feeding Behavior; Fluoxetine; Male; Norepinephr | 2014 |
Fluoxetine treatment of rat neonates significantly reduces oxidative stress in the hippocampus and in behavioral indicators of anxiety later in postnatal life.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Body Weight; Eating; Fluo | 2014 |
Chronic fluoxetine treatment suppresses plasticity (long-term potentiation) in the mature rodent primary auditory cortex in vivo.
Topics: Animals; Antidepressive Agents, Second-Generation; Auditory Cortex; Auditory Pathways; Body Weight; | 2014 |
Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depressive Disorder, | 2014 |
Fluoxetine dose and administration method differentially affect hippocampal plasticity in adult female rats.
Topics: Animals; Blood Glucose; Body Weight; CA3 Region, Hippocampal; Dose-Response Relationship, Drug; Estr | 2014 |
Role of hippocampus mitogen-activated protein kinase phosphatase-1 mRNA expression and DNA methylation in the depression of the rats with chronic unpredicted stress.
Topics: Animals; Body Weight; Chronic Disease; Depression; DNA Methylation; Dual Specificity Phosphatase 1; | 2015 |
The effects of antidepressants "fluoxetine and imipramine" on vascular abnormalities and Toll like receptor-4 expression in diabetic and non-diabetic rats exposed to chronic stress.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Blood Pressure; Blood Vessels; Body | 2015 |
Physical exercise versus fluoxetine: antagonistic effects on cortical spreading depression in Wistar rats.
Topics: Animals; Body Weight; Cortical Spreading Depression; Dose-Response Relationship, Drug; Fluoxetine; M | 2015 |
Prenatal fluoxetine exposure affects cytokine and behavioral response to an immune challenge.
Topics: Age Factors; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Body Weight; C | 2015 |
Effects of treatment with fluoxetine on mandibular development: A morphological study in rats.
Topics: Animals; Animals, Newborn; Body Weight; Female; Fluoxetine; Male; Mandible; Pregnancy; Prenatal Expo | 2015 |
Psychological stress impairs ischemia-induced neovascularization: Protective effect of fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Blood Flow Velocity; Body Weight; Cell Movement; | 2015 |
The Functional Study of a Chinese Herbal Compounded Antidepressant Medicine--Jie Yu Chu Fan Capsule on Chronic Unpredictable Mild Stress Mouse Model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Brain; Capsules; Chronic Disease; Dis | 2015 |
Neonatal serotonin reuptake inhibition reduces hypercaloric diet effects on fat mass and hypothalamic gene expression in adult rats.
Topics: Adipose Tissue; Age Factors; Animals; Animals, Newborn; Body Weight; Cholesterol; Diet; Eating; Fema | 2015 |
Effect of fluoxetine and resveratrol on testicular functions and oxidative stress in a rat model of chronic mild stress-induced depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Antioxidants; Body Weight; Depression; Fluoxetine | 2015 |
Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anticonvulsants; Body Weight; Disease Mo | 2016 |
Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Cardiomyopathies; Depression; Disease Models, Animal; | 2017 |
Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine?
Topics: Age Factors; Analysis of Variance; Animals; Body Weight; Disease Models, Animal; Eating; Female; Flu | 2017 |
Resveratrol Ameliorates the Depressive-Like Behaviors and Metabolic Abnormalities Induced by Chronic Corticosterone Injection.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Body Weight; Corticosterone; Depres | 2016 |
Zinc deficiency induces depression-like symptoms in adult rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Weig | 2008 |
Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Ca | 2008 |
Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Brain Chemistry; Brain-Derived Ne | 2009 |
Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling.
Topics: Animals; Antidepressive Agents, Second-Generation; Body Weight; Disks Large Homolog 4 Protein; Femal | 2009 |
Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice.
Topics: Aggression; Animals; Behavior, Animal; Body Weight; Chronic Disease; Depressive Disorder; Enzyme Inh | 2009 |
Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats.
Topics: Adenylyl Cyclases; Analysis of Variance; Animals; Antidepressive Agents; Body Weight; Brain; Cortico | 2009 |
Perinatal malnutrition programs sustained alterations in nitric oxide released by activated macrophages in response to fluoxetine in adult rats.
Topics: Animals; Body Weight; Cell Count; Cell Survival; Disease Models, Animal; Fluoxetine; Humans; Immune | 2009 |
Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats.
Topics: Afferent Pathways; Age Factors; Amino Acids; Animals; Animals, Newborn; Axons; Behavior, Animal; Bod | 2009 |
Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Biogenic Monoamines; Body Weight; Choice Behavior; | 2009 |
Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Expl | 2010 |
A model of binge-like eating behavior in mice that does not require food deprivation or stress.
Topics: Adiposity; Animals; Anti-Obesity Agents; Baclofen; Behavior, Animal; Binge-Eating Disorder; Body Wei | 2010 |
Effect of chronic fluoxetine treatment on male and female rat erythrocyte and prefrontal cortex fatty acid composition.
Topics: Animals; Antidepressive Agents, Second-Generation; Body Weight; Chromatography, Gas; Chromatography, | 2010 |
Postnatal fluoxetine treatment affects the development of serotonergic neurons in rats.
Topics: Animals; Animals, Newborn; Body Weight; Dentate Gyrus; Fluoxetine; Neurons; Raphe Nuclei; Rats; Sele | 2010 |
Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Dru | 2010 |
Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat.
Topics: Age Factors; Amygdala; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Wei | 2011 |
Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging.
Topics: Aging; Animals; Biomarkers; Body Weight; Depression; Disease Models, Animal; Fluoxetine; Grooming; H | 2011 |
The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Depression; Diseas | 2011 |
Long-term ovariectomy modulates the antidepressant-like action of estrogens, but not of antidepressants.
Topics: Age Factors; Animals; Antidepressive Agents; Body Weight; Desipramine; Estradiol; Estrus; Female; Fl | 2011 |
Social stress-induced hypothyroidism is attenuated by antidepressant treatment in rats.
Topics: Adipose Tissue, Brown; Analysis of Variance; Animals; Antidepressive Agents; Body Weight; Corticoste | 2012 |
Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Body Weight; Central Nervous System Stimulants; | 2012 |
Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Body Weight; Depression; Doublecortin Dom | 2011 |
Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801.
Topics: Analysis of Variance; Animals; Antibodies; Antidepressive Agents; Body Weight; Brain-Derived Neurotr | 2012 |
Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats.
Topics: Animals; Baroreflex; Basal Metabolism; Blood Pressure; Body Weight; Cardiovascular Physiological Phe | 2011 |
Effects of periadolescent fluoxetine and paroxetine on elevated plus-maze, acoustic startle, and swimming immobility in rats while on and off-drug.
Topics: Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; Body Weight; Brain; Corticosterone | 2011 |
Chronic fluoxetine treatment in middle-aged rats induces changes in the expression of plasticity-related molecules and in neurogenesis.
Topics: Animals; Antidepressive Agents, Second-Generation; Body Weight; Cell Count; Cell Proliferation; Doub | 2012 |
Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery.
Topics: Animals; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Body Weight; Bro | 2012 |
Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.
Topics: Animals; Anorexia; Benzodiazepines; Body Weight; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment.
Topics: Animals; Anorexia; Body Weight; Eating; Female; Fluoxetine; Gene Expression; Humans; Injections, Int | 2013 |
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Behavior, Animal; Body Weight; Cell Count; Cognition Disorders; Down Syndrome; Female; Fluo | 2012 |
Behavioural outcomes of perinatal maternal fluoxetine treatment.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Weight; | 2012 |
Adolescence fluoxetine increases serotonergic activity in the raphe-hippocampus axis and improves depression-like behaviors in female rats that experienced neonatal maternal separation.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Corticosterone; Corticotropin-Releasing Ho | 2013 |
Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences.
Topics: Adrenal Glands; Animals; Antidepressive Agents; Body Weight; Brain; Chronic Disease; Disease Models, | 2013 |
Impacts of early intervention with fluoxetine following early neonatal immune activation on depression-like behaviors and body weight in mice.
Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Behavior, Animal; Body W | 2013 |
A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Choice Behavior; Depression; Depressi | 2013 |
Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antidepressive Agents, Second | 2002 |
Destruction of serotonergic nerve terminals prevents fluoxetine-induced desensitization of hypothalamic 5-HT(1A) receptors.
Topics: 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenocorticotropic Hormone; Animal | 2002 |
Differential effect of polyherbal, antiobesity preparation, OB-200G in male and female mice and monosodium glutamate-treated rats.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Body Weight; Feeding Behavior; Fluoxetine; Male; Mice; | 2001 |
Neonatal treatment with fluoxetine reduces depressive behavior induced by forced swim in adult rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Depression; Escape Reaction; Fluoxetine; I | 2002 |
Influence of housing conditions on the effects of serotonergic drugs on feeding behavior in non-deprived rats.
Topics: Animals; Behavior, Animal; Body Weight; Feeding Behavior; Fluoxetine; Housing, Animal; Male; Pyrimid | 2003 |
Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus.
Topics: Animals; Body Weight; Corticotropin-Releasing Hormone; Fluoxetine; GTP-Binding Protein alpha Subunit | 2003 |
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Body Weight; Cyclobutanes; | 2003 |
Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways.
Topics: Animals; Arginine; Body Weight; Cyclic GMP; Depression, Chemical; Diarrhea; Dopamine; Drug Interacti | 2003 |
Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Blood Glucose; Body Weight; Desipramine; | 2003 |
Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Behavior, Animal; Benzodiaz | 2003 |
Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenocorticotropic Hormone; Animals; Body Weight; Brain; Co | 2004 |
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Fluids; Body Temperature; Body Weig | 2004 |
Effects of fluoxetine administration on regional galanin expression in obese Zucker rat hypothalamus.
Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Eating; Fluoxetine; Galanin; Hypothalamus; M | 2004 |
The effects of fluoxetine and buspirone on self-injurious and stereotypic behavior in adult male rhesus macaques.
Topics: Animals; Behavior, Animal; Body Weight; Buspirone; Cerebrospinal Fluid; Fluoxetine; Hydroxyindoleace | 2005 |
Paradoxical rate-dependent effect of fluoxetine on captivity-induced stereotypies in bank voles.
Topics: Analysis of Variance; Animals; Arvicolinae; Behavior, Animal; Body Weight; Dose-Response Relationshi | 2005 |
Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia.
Topics: Animals; Anorexia; Appetite Regulation; Arcuate Nucleus of Hypothalamus; Autoradiography; Body Weigh | 2005 |
Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin.
Topics: Adrenocorticotropic Hormone; Aging; Animals; Body Weight; Brain; Corticosterone; Dose-Response Relat | 2005 |
The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Blood Pressure; Body Weight; Ec | 2006 |
Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats.
Topics: Animals; Body Weight; Energy Intake; Estrus; Female; Fluoxetine; Posture; Progesterone; Rats; Rats, | 2006 |
Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents, Second-Generati | 2006 |
Chronic fluoxetine administration desensitizes the hyperglycemia but not the anorexia induced by serotonin in rats receiving fructose-enriched chow.
Topics: Animal Feed; Animals; Anorexia; Body Weight; Energy Intake; Feeding Behavior; Fluoxetine; Fructose; | 2006 |
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug | 2007 |
Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats.
Topics: Adrenal Glands; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, A | 2006 |
Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment.
Topics: Animals; Body Weight; Bromodeoxyuridine; Cell Count; Cell Differentiation; Cell Proliferation; Cell | 2007 |
Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q.
Topics: Age Factors; Animals; Anxiety, Separation; Body Weight; Depressive Disorder; Emotions; Environment; | 2007 |
Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats.
Topics: Adrenocorticotropic Hormone; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Chronic Diseas | 2007 |
Effects of fluoxetine administration on hypothalamic melanocortin system in obese Zucker rats.
Topics: Agouti-Related Protein; alpha-MSH; Animals; Appetite Depressants; Body Weight; DNA Primers; Eating; | 2008 |
Fluoxetine alters feeding behavior and leptin levels in chronically-stressed rats.
Topics: Animals; Body Weight; Chronic Disease; Estrous Cycle; Feeding Behavior; Female; Fluoxetine; Leptin; | 2008 |
Do malnutrition and fluoxetine neonatal treatment program alterations in heart morphology?
Topics: Animals; Animals, Newborn; Body Weight; Cell Count; Fluoxetine; Heart; Image Processing, Computer-As | 2008 |
Altered water-maze search behavior in adult guinea pigs following chronic prenatal ethanol exposure: lack of mitigation by postnatal fluoxetine treatment.
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Body Weight; Drug Interactions; Eating; Electric | 2008 |
Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice.
Topics: Animals; Body Weight; Copulation; Female; Fluoxetine; Genitalia, Male; Lactation; Male; Mice; Motiva | 2008 |
Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with delta 9-tetrahydrocannabinol.
Topics: Animals; Biogenic Amines; Body Weight; Clomipramine; Dronabinol; Eating; Fluoxetine; Humans; Imipram | 1980 |
Fenfluramine's appetite suppression and serotonin neurotoxicity are separable.
Topics: Animals; Anorexia; Appetite; Body Weight; Drug Combinations; Eating; Fenfluramine; Fluoxetine; Male; | 1995 |
Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat.
Topics: Animals; Body Weight; Brain; Dose-Response Relationship, Drug; Fluoxetine; Hydroxyindoleacetic Acid; | 1993 |
Accuracy and reliability of total body electrical conductivity (TOBEC) for determining body composition of rats in experimental studies.
Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Dose-Response Relationship, Drug; Electric C | 1994 |
Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Body Weight; Brain; Carrier Prot | 1994 |
A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Female; Fluoxetine; Litter Size; Male; Motor Activity | 1994 |
Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Body Weight; Electric Stimulation | 1994 |
Fluoxetine in family practice patients.
Topics: Adolescent; Adult; Age Factors; Aged; Body Weight; Depression; Drug Administration Schedule; Family | 1994 |
Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits.
Topics: Administration, Oral; Animals; Body Weight; Embryonic and Fetal Development; Female; Fetal Death; Fl | 1994 |
Fluoxetine induces vasopressin and oxytocin abnormalities in food-restricted rats given voluntary exercise: relationship to anorexia nervosa.
Topics: Animals; Anorexia Nervosa; Behavior, Animal; Body Weight; Dynorphins; Eating; Fluoxetine; Male; Oxyt | 1993 |
Radiofrequency lesions of the PVN fail to modify the effects of serotonergic drugs on food intake.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Body Weight; Clonidine; Feeding Behavior; Fenfluram | 1993 |
A time course of altered thyroid states on the noradrenergic system in rat brain by quantitative autoradiography.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 R | 1994 |
A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients.
Topics: Amitriptyline; Body Weight; Desipramine; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1993 |
Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Body Weight; Extracellular Space; Fluoxetine; Front | 1996 |
The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Autoradiography; Blood Glucose; Body Weight; Eating; Fluox | 1996 |
Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report.
Topics: Adult; Body Weight; Brain Damage, Chronic; Dose-Response Relationship, Drug; Fenfluramine; Fluoxetin | 1996 |
Effects of serotonergic agents on food-restriction-induced hyperactivity.
Topics: Animals; Antidepressive Agents, Tricyclic; Body Weight; Disease Models, Animal; Eating; Female; Fenc | 1996 |
Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine.
Topics: Administration, Oral; Animals; Appetite Depressants; Body Weight; Brain Chemistry; Catecholamines; D | 1997 |
Fluoxetine decreases fat and protein intakes but not carbohydrate intake in male rats.
Topics: Animals; Body Weight; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Dose-Response Relations | 1997 |
Modulation of immune cell function following fluoxetine administration in rats.
Topics: Analysis of Variance; Animals; Body Weight; Fluoxetine; Immunity, Cellular; Killer Cells, Natural; L | 1998 |
Black and white patients response to antidepressant treatment for major depression.
Topics: 1-Naphthylamine; Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Black People; Body Weight | 1998 |
The selective serotonin reuptake inhibitor fluoxetine reduces sexual motivation in male rats.
Topics: Animals; Body Weight; Copulation; Depression, Chemical; Ejaculation; Female; Fluoxetine; Male; Motiv | 1998 |
Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension.
Topics: Animals; Anisoles; Antidepressive Agents; Body Weight; Desipramine; Drug Interactions; Fluoxetine; H | 1998 |
Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Corticosterone; Dose-Response Relationship, Drug; Fen | 1998 |
Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Body Weight; Cytosol; Dose-Response Relationship, D | 1999 |
Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people.
Topics: Aged; Antidepressive Agents, Second-Generation; Body Weight; Female; Fluoxetine; Humans; Hyponatremi | 1999 |
Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Birth Weight; Body Weight; Cycl | 1999 |
Reduction of fat and protein intakes but not carbohydrate intake following acute and chronic fluoxetine in female rats.
Topics: Animals; Body Weight; Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Dose-Response Rel | 1999 |
Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin.
Topics: Animals; Body Weight; Ejaculation; Fluoxetine; Male; Oxytocin; Rats; Rats, Long-Evans; Selective Ser | 1999 |
Cocaine up-regulates norepinephrine transporter binding in the rat placenta.
Topics: Animals; Body Weight; Brain Chemistry; Carrier Proteins; Cell Membrane; Cocaine; Eating; Female; Flu | 1999 |
Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Body Weight; Conditioning, Psycholo | 2000 |
Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Dexfenfluramine; Eating; Fluoxetine; Immun | 2000 |
Fluoxetine increases the anorectic and long-term dopamine-depleting effects of phentermine.
Topics: Animals; Anorexia; Appetite Depressants; Biogenic Monoamines; Body Temperature; Body Weight; Brain; | 2000 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity.
Topics: Animals; Anxiety; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Fasting; Fluoxetine; Gene D | 2001 |
Studies on modulation of feeding behavior by atypical antipsychotics in female mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adipose Tissue; Animals; Antipsychotic A | 2002 |
Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction?
Topics: Animals; Body Weight; Diabetes Mellitus; Eating; Estrous Cycle; Fasting; Female; Fertility; Fluoxeti | 2002 |
Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Composition; Body Weight; Carrier Proteins; | 2002 |
Synergistic action of p-chloroamphetamine and fluoxetine on food and water consumption patterns in the rat.
Topics: Amphetamines; Animals; Body Weight; Drinking Behavior; Drug Synergism; Feeding Behavior; Female; Flu | 1978 |
Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence.
Topics: Animals; Behavior, Animal; Body Weight; Feeding Behavior; Fenfluramine; Fluoxetine; Grooming; Male; | 1992 |
Tianeptine, a specific serotonin uptake enhancer, decreases ethanol intake in rats.
Topics: Alcohol Drinking; Animals; Antidepressive Agents, Tricyclic; Body Weight; Brain; Eating; Fluoxetine; | 1992 |
Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats.
Topics: Aging; Animals; Blood Pressure; Body Weight; Fluoxetine; Heart Rate; Male; Nitroglycerin; Phenylephr | 1992 |
Weight gain during fluoxetine treatment.
Topics: Adolescent; Adult; Anxiety Disorders; Body Weight; Female; Fluoxetine; Humans; Male; Middle Aged | 1991 |
Effects of repeated administration of serotonergic agonists on diet selection and body weight in rats.
Topics: Animals; Body Weight; Diet; Drug Administration Schedule; Fenfluramine; Fluoxetine; Indoles; Male; R | 1991 |
Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
Topics: Body Weight; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Time Factors | 1990 |
Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice.
Topics: Animals; Body Composition; Body Weight; Drug Administration Schedule; Eating; Female; Fluoxetine; In | 1990 |
The fluoxetine treatment of low-weight, chronic bulimia nervosa.
Topics: Adult; Anxiety Disorders; Body Weight; Bulimia; Depressive Disorder; Feeding Behavior; Female; Fluox | 1990 |
Attenuation of alcohol intake by a serotonin uptake inhibitor: evidence for mediation through the renin-angiotensin system.
Topics: Alcohol Drinking; Animals; Body Weight; Enalapril; Fluoxetine; Male; Rats; Rats, Inbred Strains; Ref | 1988 |
An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Calcitonin; Dextroamphetamine; Drug Toleran | 1987 |
Abuse of fluoxetine by a patient with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Weight; Depressive Disorder; Female; Fluoxetine; Humans; Propylamines; | 1987 |